| Literature DB >> 31043860 |
Tianbo Liu1, Liangliang Jiang1, Libo Yu1, Tingting Ge1, Jing Wang1, Hongyu Gao2.
Abstract
BACKGROUND: Tumor necrosis factor-a-induced protein 8 (TNFAIP8) presented a elevated expression in endometrial cancer (EC). However, the relationship of TNFAIP8 gene polymorphisms with EC risk remains unclear. This case-control study aimed to investigate the effect of single nucleotide polymorphisms (SNPs) in TNFAIP8 on northern Chinese women with EC.Entities:
Keywords: Endometrial cancer; Polymorphism; Protein expression; Susceptibility; TNFAIP8
Year: 2019 PMID: 31043860 PMCID: PMC6480735 DOI: 10.1186/s12935-019-0827-9
Source DB: PubMed Journal: Cancer Cell Int ISSN: 1475-2867 Impact factor: 5.722
Characteristics of 226 endometrial cancer cases and 248 cancer-free controls
| Characteristics | Cases | Controls |
|
|---|---|---|---|
| Age | 53.92 ± 8.396 | 53.44 ± 8.692 | 0.545 |
| BMI | 25.59 ± 3.576 | 23.79 ± 4.919 | < 0.001 |
| Age at menarche | 14.60 ± 1.497 | 15.06 ± 1.886 | 0.003 |
| Menopausal status | < 0.001 | ||
| Pre-menopausal | 86 | 195 | |
| Post-menopausal | 140 | 53 | |
| Parity | 0.905 | ||
| Nulliparity | 30 | 32 | |
| Multiparity | 196 | 216 | |
| Hypertension | < 0.001 | ||
| No | 163 | 216 | |
| Yes | 63 | 32 | |
| Diabetes | 0.053 | ||
| No | 200 | 232 | |
| Yes | 26 | 16 | |
| Smoking history | 0.759 | ||
| No | 206 | 228 | |
| Yes | 20 | 20 | |
BMI body mass index
aTwo-sided Chi-squared test or Fisher’s test or student’s t test
Genotype frequencies of TNFAIP8 gene polymorphism among patients and controls and their associations with the susceptibility of endometrial cancer
| Variables | Cases (%) n = 226 | Controls (%) n = 248 |
| Crude OR (95% CI) |
| Adjust OR (95% CI) |
|
|---|---|---|---|---|---|---|---|
| Genotypes | |||||||
| rs11064 | 0.029 | ||||||
| AA | 138 (61.1) | 178 (71.8) | |||||
| AG | 70 (31.0) | 60 (24.2) | 1.505 (0.998–2.268) | 0.051 | 1.571 (0.972–2.539) | 0.065 | |
| GG | 18 (7.9) | 10 (4.0) | 2.322 (1.039–5.190) | 0.040 | 2.582 (1.034–6.445) | 0.042 | |
| AG + GG | 88 (38.9) | 70 (28.2) | 1.622 (1.104–2.382) | 0.014 | 1.778 (1.134–2.782) | 0.012 | |
| rs1045241 | 0.529 | ||||||
| CC | 143 (63.3) | 167 (67.3) | |||||
| CT | 71 (31.4) | 72 (29.1) | 1.152 (0.775–1.712) | 0.485 | 1.144 (0.906–2.299) | 0.122 | |
| TT | 12 (5.3) | 9 (3.6) | 1.557 (0.638–3.802) | 0.331 | 1.980 (0.699–5.607) | 0.198 | |
| CT + TT | 83 (36.7) | 81 (32.7) | 1.197 (0.819–1.748) | 0.353 | 1.501 (0.961–2.344) | 0.074 | |
| rs1045242 | 0.197 | ||||||
| AA | 144 (63.7) | 177 (71.4) | |||||
| AG | 74 (32.7) | 65 (26.2) | 1.399 (0.939–2.086) | 0.099 | 1.568 (0.980–2.507) | 0.061 | |
| GG | 8 (3.6) | 6 (2.4) | 1.639 (0.556–4.831) | 0.370 | 2.695 (0.799–9.084) | 0.110 | |
| AG + GG | 82 (36.3) | 71 (28.6) | 1.420 (0.965–2.089) | 0.076 | 1.651 (1.049–2.599) | 0.030 | |
| Alleles | |||||||
| rs11064 | |||||||
| A | 346 (76.5) | 416 (83.9) | |||||
| G | 106 (23.5) | 80 (16.1) | 0.005 | 1.593 (1.153–2.201) | 0.005 | 1.719 (1.180–2.506) | 0.005 |
| rs1045241 | |||||||
| C | 357 (79.0) | 406 (81.9) | |||||
| T | 95 (21.0) | 90 (18.1) | 0.265 | 1.200 (0.870–1.656) | 0.265 | 1.457 (1.001–2.120) | 0.050 |
| rs1045242 | |||||||
| A | 362 (80.1) | 419 (84.5) | |||||
| G | 90 (19.9) | 77(15.5) | 0.077 | 1.353 (0.968–1.892) | 0.077 | 1.636 (1.107–2.417) | 0.014 |
BMI body mass index, OR odds ratio, CI confidence interval
aTwo-sided Chi-squared test
bData were calculated by logistic regression, adjusted for age, smoking history, BIM, menopausal status
Fig. 1Immunohistochemical staining of TNFAIP8 protein in endometrial cancer tissues. TNFAIP8 immunoreactivity was observed mainly in the cytoplasm. Staining for each specimen is shown at magnification ×400. TNFAIP8 protein low expression slides (a); TNFAIP8 protein high expression slides (b)
Association of different SNPs in the TNFAIP8 gene with TNFAIP8 protein expression from 226 patients with endometrial cancer
| SNP | TNFAIP8 expression |
| |
|---|---|---|---|
| High (%) (n = 85) | Low (%) (n = 141) | ||
| Genotypes | |||
| rs11064 | |||
| AA | 42 (49.4) | 96 (68.1) | |
| AG | 33 (38.8) | 37 (26.2) | |
| GG | 10 (11.8) | 8 (5.7) | 0.015 |
| AG + GG | 43 (50.6) | 45 (31.9) | 0.005 |
| rs1045241 | |||
| CC | 48 (56.5) | 95 (67.4) | |
| CT | 32 (37.6) | 39 (27.7) | |
| TT | 5 (5.9) | 7 (4.9) | 0.229 |
| CT + TT | 37 (43.5) | 46 (32.6) | 0.099 |
| rs1045242 | |||
| AA | 46 (54.1) | 98 (69.5) | |
| AG | 34 (40.0) | 40 (28.4) | |
| GG | 5 (5.9) | 3 (2.1) | 0.060 |
| AG + GG | 39 (45.9) | 43 (30.5) | 0.020 |
aTwo-sided Chi-squared test or Fisher’s test
The association between rs11064, rs1045241 and rs1045242 and clinicopathological characteristics of endometrial cancer
| Characteristics | rs11064 |
| rs1045241 |
| rs1045242 |
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AA | AG | GG | AG + GG | CC | CT | TT | CC + CT | AA | AG | GG | AG + GG | ||||
| FIGO stage | 0.011 | 0.174 | 0.103 | ||||||||||||
| I | 108 | 60 | 10 | 70 | 0.425 | 115 | 54 | 9 | 63 | 0.075 | 114 | 58 | 6 | 64 | 0.041 |
| II | 23 | 6 | 3 | 9 | 22 | 8 | 2 | 10 | 24 | 7 | 1 | 8 | |||
| III–IV | 7 | 4 | 5 | 9 | 6 | 9 | 1 | 10 | 6 | 9 | 1 | 10 | |||
| Histologic grade | 0.718 | 0.678 | 0.658 | ||||||||||||
| G1 | 56 | 29 | 5 | 34 | 0.966 | 57 | 28 | 5 | 33 | 0.554 | 56 | 30 | 4 | 34 | 0.383 |
| G2 | 60 | 29 | 11 | 40 | 66 | 28 | 6 | 34 | 68 | 29 | 3 | 32 | |||
| G3 | 22 | 12 | 2 | 14 | 20 | 15 | 1 | 16 | 20 | 15 | 1 | 16 | |||
| Histological type | 0.445 | 0.469 | 0.464 | ||||||||||||
| EC | 112 | 57 | 17 | 74 | 1.000 | 114 | 61 | 11 | 72 | 0.182 | 116 | 62 | 8 | 70 | |
| Non-EC | 26 | 13 | 1 | 14 | 29 | 10 | 1 | 11 | 28 | 12 | 0 | 12 | |||
| Depth of MI | 0.047 | 0.153 | 0.088 | ||||||||||||
| < 50% | 95 | 53 | 17 | 70 | 0.077 | 98 | 98 | 8 | 65 | 0.114 | 97 | 60 | 6 | 66 | 0.034 |
| ≥ 50% | 43 | 17 | 1 | 18 | 45 | 45 | 4 | 18 | 47 | 14 | 2 | 16 | |||
| LVSI | 0.708 | 0.338 | 0.562 | ||||||||||||
| No | 118 | 63 | 16 | 79 | 0.350 | 122 | 122 | 10 | 75 | 0.274 | 123 | 67 | 7 | 74 | 0.297 |
| Yes | 20 | 7 | 2 | 9 | 21 | 21 | 2 | 8 | 21 | 7 | 1 | 8 | |||
| LN metastasis | 0.048 | 0.702 | 0.934 | ||||||||||||
| No | 122 | 62 | 12 | 74 | 0.351 | 123 | 123 | 10 | 73 | 0.679 | 124 | 65 | 7 | 72 | 0.718 |
| Yes | 16 | 8 | 6 | 14 | 20 | 20 | 2 | 10 | 20 | 9 | 1 | 10 | |||
| CA-125 level | 0.261 | 0.296 | 0.115 | ||||||||||||
| ≤ 35 U/mL | 102 | 59 | 14 | 73 | 0.113 | 108 | 108 | 8 | 67 | 0.283 | 106 | 63 | 6 | 69 | 0.063 |
| > 35 U/Ml | 36 | 11 | 4 | 15 | 35 | 35 | 4 | 16 | 38 | 11 | 2 | 13 | |||
| P53 | 0.198 | 0.092 | 0.141 | ||||||||||||
| Negative | 75 | 34 | 13 | 47 | 0.890 | 83 | 31 | 8 | 39 | 0.108 | 84 | 33 | 5 | 38 | 0.082 |
| Positive | 63 | 36 | 5 | 41 | 60 | 40 | 4 | 44 | 60 | 41 | 3 | 44 | |||
| ER | 0.631 | 0.516 | 0.706 | ||||||||||||
| Negative | 33 | 16 | 6 | 22 | 0.853 | 36 | 18 | 1 | 19 | 0.630 | 34 | 20 | 1 | 21 | 0.736 |
| Positive | 105 | 54 | 12 | 66 | 107 | 53 | 11 | 66 | 110 | 54 | 7 | 61 | |||
| PR | 0.604 | 0.860 | 0.439 | ||||||||||||
| Negative | 49 | 20 | 6 | 26 | 0.353 | 49 | 23 | 3 | 26 | 0.651 | 49 | 22 | 4 | 26 | 0.722 |
| Positive | 89 | 50 | 12 | 62 | 94 | 48 | 9 | 57 | 95 | 52 | 4 | 56 | |||
| Ki67 | 0.47 | 0.117 | 0.704 | ||||||||||||
| Negative | 34 | 14 | 6 | 20 | 0.743 | 33 | 20 | 1 | 21 | 0.854 | 32 | 20 | 2 | 22 | 0.435 |
| Positive | 104 | 56 | 12 | 68 | 110 | 51 | 11 | 66 | 112 | 54 | 6 | 60 | |||
FIGO International Federation of Gynecology and Obstetrics, G1 well, G2 moderate, G3 poor, EC endometrial cancer, MI myometrial invasion, LVSI lymphovascular space involvement, LN lymph node
aTwo-sided Chi-squared test or Fisher’s test